Bitfarms Addresses Riot's Misleading Claims Amid Acquisition Talks

Bitfarms responds to Riot's claims, emphasizing its commitment to shareholder value and strategic acquisitions. (Read More)

View Details

Riot Platforms Urges Bitfarms Shareholders to Elect New Directors at Upcoming Meeting

Riot Platforms calls for Bitfarms shareholders to vote for new board members to improve governance ahead of a crucial special meeting. (Read More)

View Details

Bitfarms responds to Riot Platforms proposed board changes

Riot Platforms called the recent board changes at Bitfarms a step in the right direction, but stressed that more change is needed.

View Details

Digital Health Stock Butterfly Network Inc. (NYSE: BFLY) Gains on Expansion News

September 4, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas, including biotech stocks and digital health stocks, reports on trading for Butterfly Network Inc. (NYSE: BFLY), a digital health company transforming care with portable semiconductor-based ultrasound technology and intuitive software.

View Details

Telemedicine and Weight Loss Stocks to Watch

September 4, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform covering health and wellness issues a snapshot looking at news and developments for the telemedicine and weight loss market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV), a portfolio holdings company, focused on e-commerce technology, digital assets and consumer-focused investments.

View Details

Riot Platforms targets remaining 2 Bitfarms board members replacement

Riot Platforms has intensified its efforts to acquire rival Bitcoin miner Bitfarms by issuing an open letter to the firm’s shareholders on Sept. 3. In the letter, Riot announced that it had lowered its request for board seats at Bitfarms to two independent directors following recent removals while also criticizing several of the company’s recent decisions. […]

The post Riot Platforms targets remaining 2 Bitfarms board members’ replacement appeared first on CryptoSlate.

View Details

Riot Platforms urges Bitfarms board changes ahead of crucial October meeting

Riot Platforms urges further changes to Bitfarms board, proposing two independent directors ahead of a special meeting in October.

View Details

Billionaire Bitcoiner slams UK tax system, leaves for Swiss Bitcoin city: Report

Christian Angermayer claimed the United Kingdoms latest tax proposal for non-doms would be a huge mistake and be a bigger act of national self-harm than Brexit.

View Details

Crypto Biz: Bitfarms gets new board after months of power struggles

Bitfarms and Riot Platforms settle months of corporate disputes with board review, while BlackRock moves for changes to Bitcoin ETF withdrawals. 

View Details

Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials

September 26, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications.

View Details

Bitfarms and Riot Platforms Reach Settlement Agreement

Bitfarms Ltd. and Riot Platforms Inc. announce a settlement agreement ahead of the Special Meeting of Bitfarms Shareholders, with significant changes to the Board of Directors. (Read More)

View Details

Riot Platforms Announces Settlement Agreement with Bitfarms, Board Changes Enacted

Riot Platforms and Bitfarms Ltd. reach a settlement agreement, resulting in board changes and withdrawal of a shareholder meeting requisition. (Read More)

View Details

Wave Life Sciences Ltd. (Nasdaq: WVE) Gains on Clinical Trial News

September 24, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.

View Details

Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD

September 24, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech technology stocks reports on trading and news for Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases.

View Details

Bitfarms, Riot settle dispute with board changes

Bitfarms board will see Andrés Finkielsztain step down, while Amy Freedman and a sixth member will join the board.

View Details

Stocks to Watch Battling the Opioid Epidemic

September 20, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to investing platform covering cannabis stocks releases an industry snapshot looking at the battle against dangerous drugs, including fentanyl, featuring Greenlane Holdings, Inc. (NASDAQ:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products.

View Details

Breaking Medical Technology News: Aethlon (NASDAQ: AEMD) Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

SAN DIEGO - September 19, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda (pembrolizumab) or Opdivo (nivolumab) (AEMD-2022-06 Hemopurifier Study).

View Details

Immunotherapy Clinical Trial News - Stocks to Watch

September 19, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections.

View Details

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) to Present at Virtual Investor Conferences in September

SAN DIEGO - September 17, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September

View Details

Cancer's Solid Tumors Market - the Stocks to Watch

September 17, 2024 (Investorideas.com Newswire) Stocks mentioned-Aethlon Medical, Inc. (Nasdaq: AEMD), Immuneering (Nasdaq: IMRX), Merck (NYSE: MRK), AstraZeneca (Nasdaq: AZN) Roche (OTCQX: RHHBY).

View Details